BioSpace News Archive

The partners will combine Miromatrix’s single-use bioengineered liver with Baxter’s PrisMax system, which is designed to provide individualized therapies to patients.

GSK has dropped two assets, an investigational celiac disease therapeutic and a Staphylococcus aureus vaccine hopeful, from its pipeline.

Novartis is cleaning house, cutting its Huntington’s disease program along with several others. The company announced multiple program stops and delays in its full-year 2022 report Wednesday.

As the 118th Congress kicks into gear, biopharma industry observers speculate that 2023 may be a challenging year.

The FDA asked Taysha Gene Therapies to dose more patients in a double-blinded, placebo-controlled trial before submitting a BLA for its giant axonal neuropathy candidate.

Ghent, Belgium – 1 February 2023– Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces the grant of an additional US patent for its DSR program.

Occlutech Holding AG Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, appoints Dr. Morwan Choli as the new Vice President of Regulatory Affairs & Quality.

AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announced the appointment of Jeff Goater as Chair of the AviadoBio Board of Directors, effective immediately.

Scenic Biotech announced that it has entered into a Cooperative Research and Development Agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health, to support its therapeutic program for the treatment of Niemann-Pick Type C disease, which is a severe, progressive and lethal neurological disorder.

Beactica Therapeutics AB announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BEA-17 for the treatment of glioblastoma.